Meloxicam (Mobic): a review of its pharmacological and clinical profile
Meloxicam (Mobic) is a new nonsteroidal anti-inflammatory drug (NSAID) derived from enolic acid, exhibiting selectivity for cyclooxygenase (COX)-2 over COX-1. Meloxicam has shown potent anti-inflammatory and analgesic activity together with low gastrointestinal toxicity in animal models. It is a pot...
Gespeichert in:
| Veröffentlicht in: | Folia Pharmacologica Japonica 2002, Vol.120(6), pp.391-397 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | jpn |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 397 |
|---|---|
| container_issue | 6 |
| container_start_page | 391 |
| container_title | Folia Pharmacologica Japonica |
| container_volume | 120 |
| creator | OGINO, Keiko SAITO, Kazushige OSUGI, Takeshi SATOH, Hisashi |
| description | Meloxicam (Mobic) is a new nonsteroidal anti-inflammatory drug (NSAID) derived from enolic acid, exhibiting selectivity for cyclooxygenase (COX)-2 over COX-1. Meloxicam has shown potent anti-inflammatory and analgesic activity together with low gastrointestinal toxicity in animal models. It is a potent inhibitor not only of acute exudation in adjuvant arthritis in the rat, but also of bone and cartilage destruction. The therapeutic range of meloxicam in the rat, with regard to inhibition of adjuvant arthritis, was several times greater than that of other NSAIDs. Meloxicam in therapeutic doses was found to have no effect on bleeding time or platelet aggregation in healthy volunteers. In clinical studies, meloxicam has shown reliable efficacy against rheumatoid arthritis, osteoarthritis, lumbago (low back pain), scapulohumeral periarthritis, and neck-shoulder-arm syndrome with low gastrointestinal toxicity. |
| doi_str_mv | 10.1254/fpj.120.391 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1254_fpj_120_391</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>12528470</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2951-879f1efc476a757a2388d3de58c292f27c7419899eb396f76abe892cb18134f3</originalsourceid><addsrcrecordid>eNpFkEtLAzEUhYMottSu3EuWikzNYzJJ3JWiVWhx0_2QySQ1JdMMSX303xttqZv74H73wDkAXGM0wYSVD7bf5AFNqMRnYIhpyQtBJT8HQ4QwK1gl8QCMU3INQowTXlF8CQb5lYiSoyGYL40P306rDt4uQ-P03SNUMJpPZ75gsNDtEuzfVeyUDj6sM-ih2rZQe7f9W_oYrPPmClxY5ZMZH_sIrJ6fVrOXYvE2f51NF4UmkuFCcGmxsbrkleKMK0KFaGlrmMh3YgnXvMRSSGkaKiubqcYISXSDRfZm6QjcH2R1DClFY-s-uk7FfY1R_RtInQPJA6pzIJm-OdD9R9OZ9p892s_A9ABs0k6tzQlQcee0Nyex6liz6Ommcyq12dIfGlFx0Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Meloxicam (Mobic): a review of its pharmacological and clinical profile</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>OGINO, Keiko ; SAITO, Kazushige ; OSUGI, Takeshi ; SATOH, Hisashi</creator><creatorcontrib>OGINO, Keiko ; SAITO, Kazushige ; OSUGI, Takeshi ; SATOH, Hisashi</creatorcontrib><description>Meloxicam (Mobic) is a new nonsteroidal anti-inflammatory drug (NSAID) derived from enolic acid, exhibiting selectivity for cyclooxygenase (COX)-2 over COX-1. Meloxicam has shown potent anti-inflammatory and analgesic activity together with low gastrointestinal toxicity in animal models. It is a potent inhibitor not only of acute exudation in adjuvant arthritis in the rat, but also of bone and cartilage destruction. The therapeutic range of meloxicam in the rat, with regard to inhibition of adjuvant arthritis, was several times greater than that of other NSAIDs. Meloxicam in therapeutic doses was found to have no effect on bleeding time or platelet aggregation in healthy volunteers. In clinical studies, meloxicam has shown reliable efficacy against rheumatoid arthritis, osteoarthritis, lumbago (low back pain), scapulohumeral periarthritis, and neck-shoulder-arm syndrome with low gastrointestinal toxicity.</description><identifier>ISSN: 0015-5691</identifier><identifier>EISSN: 1347-8397</identifier><identifier>DOI: 10.1254/fpj.120.391</identifier><identifier>PMID: 12528470</identifier><language>jpn</language><publisher>Japan: The Japanese Pharmacological Society</publisher><subject>Animals ; Anti-Inflammatory Agents, Non-Steroidal - administration & dosage ; Anti-Inflammatory Agents, Non-Steroidal - adverse effects ; Anti-Inflammatory Agents, Non-Steroidal - pharmacology ; Arthritis, Experimental - drug therapy ; Arthritis, Rheumatoid - drug therapy ; Clinical Trials as Topic ; cyclooxygenase (COX)-2 ; Cyclooxygenase 2 ; Enzyme Inhibitors - administration & dosage ; Enzyme Inhibitors - adverse effects ; Enzyme Inhibitors - pharmacology ; Gastric Mucosa - drug effects ; Gastrointestinal Hemorrhage - chemically induced ; Humans ; Inflammation - drug therapy ; Isoenzymes - antagonists & inhibitors ; Meloxicam ; Membrane Proteins ; Mobic ; non-steroidal anti-inflammatory drugs ; Pain - drug therapy ; Platelet Aggregation - drug effects ; Prostaglandin-Endoperoxide Synthases ; prostaglandins ; Rats ; Thiazines - administration & dosage ; Thiazines - adverse effects ; Thiazines - pharmacology ; Thiazoles - administration & dosage ; Thiazoles - adverse effects ; Thiazoles - pharmacology</subject><ispartof>Folia Pharmacologica Japonica, 2002, Vol.120(6), pp.391-397</ispartof><rights>2002 by The Japanese Pharmacological Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2951-879f1efc476a757a2388d3de58c292f27c7419899eb396f76abe892cb18134f3</citedby><cites>FETCH-LOGICAL-c2951-879f1efc476a757a2388d3de58c292f27c7419899eb396f76abe892cb18134f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4021,27921,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12528470$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>OGINO, Keiko</creatorcontrib><creatorcontrib>SAITO, Kazushige</creatorcontrib><creatorcontrib>OSUGI, Takeshi</creatorcontrib><creatorcontrib>SATOH, Hisashi</creatorcontrib><title>Meloxicam (Mobic): a review of its pharmacological and clinical profile</title><title>Folia Pharmacologica Japonica</title><addtitle>Nihon Yakurigaku Zasshi</addtitle><description>Meloxicam (Mobic) is a new nonsteroidal anti-inflammatory drug (NSAID) derived from enolic acid, exhibiting selectivity for cyclooxygenase (COX)-2 over COX-1. Meloxicam has shown potent anti-inflammatory and analgesic activity together with low gastrointestinal toxicity in animal models. It is a potent inhibitor not only of acute exudation in adjuvant arthritis in the rat, but also of bone and cartilage destruction. The therapeutic range of meloxicam in the rat, with regard to inhibition of adjuvant arthritis, was several times greater than that of other NSAIDs. Meloxicam in therapeutic doses was found to have no effect on bleeding time or platelet aggregation in healthy volunteers. In clinical studies, meloxicam has shown reliable efficacy against rheumatoid arthritis, osteoarthritis, lumbago (low back pain), scapulohumeral periarthritis, and neck-shoulder-arm syndrome with low gastrointestinal toxicity.</description><subject>Animals</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - administration & dosage</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - adverse effects</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - pharmacology</subject><subject>Arthritis, Experimental - drug therapy</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Clinical Trials as Topic</subject><subject>cyclooxygenase (COX)-2</subject><subject>Cyclooxygenase 2</subject><subject>Enzyme Inhibitors - administration & dosage</subject><subject>Enzyme Inhibitors - adverse effects</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Gastric Mucosa - drug effects</subject><subject>Gastrointestinal Hemorrhage - chemically induced</subject><subject>Humans</subject><subject>Inflammation - drug therapy</subject><subject>Isoenzymes - antagonists & inhibitors</subject><subject>Meloxicam</subject><subject>Membrane Proteins</subject><subject>Mobic</subject><subject>non-steroidal anti-inflammatory drugs</subject><subject>Pain - drug therapy</subject><subject>Platelet Aggregation - drug effects</subject><subject>Prostaglandin-Endoperoxide Synthases</subject><subject>prostaglandins</subject><subject>Rats</subject><subject>Thiazines - administration & dosage</subject><subject>Thiazines - adverse effects</subject><subject>Thiazines - pharmacology</subject><subject>Thiazoles - administration & dosage</subject><subject>Thiazoles - adverse effects</subject><subject>Thiazoles - pharmacology</subject><issn>0015-5691</issn><issn>1347-8397</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkEtLAzEUhYMottSu3EuWikzNYzJJ3JWiVWhx0_2QySQ1JdMMSX303xttqZv74H73wDkAXGM0wYSVD7bf5AFNqMRnYIhpyQtBJT8HQ4QwK1gl8QCMU3INQowTXlF8CQb5lYiSoyGYL40P306rDt4uQ-P03SNUMJpPZ75gsNDtEuzfVeyUDj6sM-ih2rZQe7f9W_oYrPPmClxY5ZMZH_sIrJ6fVrOXYvE2f51NF4UmkuFCcGmxsbrkleKMK0KFaGlrmMh3YgnXvMRSSGkaKiubqcYISXSDRfZm6QjcH2R1DClFY-s-uk7FfY1R_RtInQPJA6pzIJm-OdD9R9OZ9p892s_A9ABs0k6tzQlQcee0Nyex6liz6Ommcyq12dIfGlFx0Q</recordid><startdate>2002</startdate><enddate>2002</enddate><creator>OGINO, Keiko</creator><creator>SAITO, Kazushige</creator><creator>OSUGI, Takeshi</creator><creator>SATOH, Hisashi</creator><general>The Japanese Pharmacological Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>2002</creationdate><title>Meloxicam (Mobic): a review of its pharmacological and clinical profile</title><author>OGINO, Keiko ; SAITO, Kazushige ; OSUGI, Takeshi ; SATOH, Hisashi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2951-879f1efc476a757a2388d3de58c292f27c7419899eb396f76abe892cb18134f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>jpn</language><creationdate>2002</creationdate><topic>Animals</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - administration & dosage</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - adverse effects</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - pharmacology</topic><topic>Arthritis, Experimental - drug therapy</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Clinical Trials as Topic</topic><topic>cyclooxygenase (COX)-2</topic><topic>Cyclooxygenase 2</topic><topic>Enzyme Inhibitors - administration & dosage</topic><topic>Enzyme Inhibitors - adverse effects</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Gastric Mucosa - drug effects</topic><topic>Gastrointestinal Hemorrhage - chemically induced</topic><topic>Humans</topic><topic>Inflammation - drug therapy</topic><topic>Isoenzymes - antagonists & inhibitors</topic><topic>Meloxicam</topic><topic>Membrane Proteins</topic><topic>Mobic</topic><topic>non-steroidal anti-inflammatory drugs</topic><topic>Pain - drug therapy</topic><topic>Platelet Aggregation - drug effects</topic><topic>Prostaglandin-Endoperoxide Synthases</topic><topic>prostaglandins</topic><topic>Rats</topic><topic>Thiazines - administration & dosage</topic><topic>Thiazines - adverse effects</topic><topic>Thiazines - pharmacology</topic><topic>Thiazoles - administration & dosage</topic><topic>Thiazoles - adverse effects</topic><topic>Thiazoles - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>OGINO, Keiko</creatorcontrib><creatorcontrib>SAITO, Kazushige</creatorcontrib><creatorcontrib>OSUGI, Takeshi</creatorcontrib><creatorcontrib>SATOH, Hisashi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Folia Pharmacologica Japonica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>OGINO, Keiko</au><au>SAITO, Kazushige</au><au>OSUGI, Takeshi</au><au>SATOH, Hisashi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Meloxicam (Mobic): a review of its pharmacological and clinical profile</atitle><jtitle>Folia Pharmacologica Japonica</jtitle><addtitle>Nihon Yakurigaku Zasshi</addtitle><date>2002</date><risdate>2002</risdate><volume>120</volume><issue>6</issue><spage>391</spage><epage>397</epage><pages>391-397</pages><issn>0015-5691</issn><eissn>1347-8397</eissn><abstract>Meloxicam (Mobic) is a new nonsteroidal anti-inflammatory drug (NSAID) derived from enolic acid, exhibiting selectivity for cyclooxygenase (COX)-2 over COX-1. Meloxicam has shown potent anti-inflammatory and analgesic activity together with low gastrointestinal toxicity in animal models. It is a potent inhibitor not only of acute exudation in adjuvant arthritis in the rat, but also of bone and cartilage destruction. The therapeutic range of meloxicam in the rat, with regard to inhibition of adjuvant arthritis, was several times greater than that of other NSAIDs. Meloxicam in therapeutic doses was found to have no effect on bleeding time or platelet aggregation in healthy volunteers. In clinical studies, meloxicam has shown reliable efficacy against rheumatoid arthritis, osteoarthritis, lumbago (low back pain), scapulohumeral periarthritis, and neck-shoulder-arm syndrome with low gastrointestinal toxicity.</abstract><cop>Japan</cop><pub>The Japanese Pharmacological Society</pub><pmid>12528470</pmid><doi>10.1254/fpj.120.391</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0015-5691 |
| ispartof | Folia Pharmacologica Japonica, 2002, Vol.120(6), pp.391-397 |
| issn | 0015-5691 1347-8397 |
| language | jpn |
| recordid | cdi_crossref_primary_10_1254_fpj_120_391 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Animals Anti-Inflammatory Agents, Non-Steroidal - administration & dosage Anti-Inflammatory Agents, Non-Steroidal - adverse effects Anti-Inflammatory Agents, Non-Steroidal - pharmacology Arthritis, Experimental - drug therapy Arthritis, Rheumatoid - drug therapy Clinical Trials as Topic cyclooxygenase (COX)-2 Cyclooxygenase 2 Enzyme Inhibitors - administration & dosage Enzyme Inhibitors - adverse effects Enzyme Inhibitors - pharmacology Gastric Mucosa - drug effects Gastrointestinal Hemorrhage - chemically induced Humans Inflammation - drug therapy Isoenzymes - antagonists & inhibitors Meloxicam Membrane Proteins Mobic non-steroidal anti-inflammatory drugs Pain - drug therapy Platelet Aggregation - drug effects Prostaglandin-Endoperoxide Synthases prostaglandins Rats Thiazines - administration & dosage Thiazines - adverse effects Thiazines - pharmacology Thiazoles - administration & dosage Thiazoles - adverse effects Thiazoles - pharmacology |
| title | Meloxicam (Mobic): a review of its pharmacological and clinical profile |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T11%3A33%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Meloxicam%20(Mobic):%20a%20review%20of%20its%20pharmacological%20and%20clinical%20profile&rft.jtitle=Folia%20Pharmacologica%20Japonica&rft.au=OGINO,%20Keiko&rft.date=2002&rft.volume=120&rft.issue=6&rft.spage=391&rft.epage=397&rft.pages=391-397&rft.issn=0015-5691&rft.eissn=1347-8397&rft_id=info:doi/10.1254/fpj.120.391&rft_dat=%3Cpubmed_cross%3E12528470%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/12528470&rfr_iscdi=true |